Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
USFDA completes PAI of Lupin’s biotech facility in Pune
Subscribe To Our Newsletter & Stay Updated
